Having trouble accessing articles? Reset your cache.

CDER Expands New Review Scheme

FDA's Center for Drug Evaluation and Research is expanding the use of new review procedures that it has been phasing in over the last two years. As of Oct. 1, the start of the federal government's fiscal year, NDAs for all new molecular entities (NMEs), as well as all original BLAs and efficacy supplements for new or expanded indications, will be processed using the 21st Century Review procedure.

The new procedures incorporate planning of post-market safety requirements early

Read the full 778 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE